Personalized vaccine trains immune system to attack kidney cancer blood vessels

NCT ID NCT05127824

Recruiting now Disease control Sponsor: Jodi Maranchie Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests a combination of two treatments for people with localized clear cell kidney cancer that can be surgically removed. The first is a personalized vaccine made from the patient's own immune cells, designed to target proteins found on tumor blood vessels. The second is cabozantinib, a daily oral drug that blocks cancer growth. The goal is to see if this combination can boost the immune system's ability to fight the cancer and reduce the tumor's blood supply, while also checking for safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized dendritic cell vaccine (made from the patient's own immune cells) plus cabozantinib (a targeted cancer drug)
What this could lead to: If successful, this combination could become a new treatment option for localized kidney cancer, potentially reducing the risk of recurrence after surgery.
What could go wrong: This is an early-phase trial with only 42 participants, so results may not apply to all patients. The vaccine is personalized and complex to produce, and side effects from the combination are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, RENAL CELL

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UPMC Department of Urology
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.